TECLens, .

TECLens, .
Stealth ModeDeveloping non-invasive corneal cross-linking technology for vision correction.
About
What does TECLens, . do?
TECLens is a clinical-stage ophthalmic medical device company pioneering non-invasive, personalized corneal cross-linking technology (qCXL™) for vision correction. Their innovative CXLens® system uses patterned ultraviolet (UV) light to gently reshape the cornea with continuous biomechanical control, offering a comfortable, safe, and effective alternative to traditional refractive surgeries. The company aims to set a new standard in precision, accessibility, and patient experience, redefining vi…
Where is TECLens, . headquartered?
TECLens, . is headquartered in Stamford, United States.
What industry does TECLens, . operate in?
TECLens, . operates in Medical Device, Ophthalmology, HealthTech, Biotech, Corneal Cross-linking, Refractive Surgery.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaña. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
A research organization quantifying impact-focused investments using advanced AI methods to create rigorous, comparable metrics.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 7 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.